About Fibrinogen gamma chain
Fibrinogen gamma chain (FGG) is a protein
from Homo sapiens identified by UniProt accession
P02679, 453 residues long.
MolForge cross-references it against 0 known binders and
296 disease associations.
Target properties
| Protein name | Fibrinogen gamma chain |
|---|
| UniProt accession | P02679 |
|---|
| Gene | FGG |
|---|
| Organism | Homo sapiens |
|---|
| Length | 453 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (296)
Diseases linked to this target (Open Targets).
- familial dysfibrinogenemia · score 0.80
- congenital afibrinogenemia · score 0.76
- Familial afibrinogenemia · score 0.74
- familial hypodysfibrinogenemia · score 0.63
- Hypofibrinogenemia · score 0.61
- cancer · score 0.59
- hemorrhage · score 0.58
- Noonan syndrome · score 0.53
- thrombotic disease · score 0.51
- hypertrophic cardiomyopathy · score 0.50
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P02679-F1 | alphafold | PREDICTED | 85.51 | — |
Amino-acid sequence (453 residues)
MSWSLHPRNL ILYFYALLFL SSTCVAYVAT RDNCCILDER FGSYCPTTCG IADFLSTYQT KVDKDLQSLE DILHQVENKT SEVKQLIKAI QLTYNPDESS KPNMIDAATL KSRKMLEEIM KYEASILTHD SSIRYLQEIY NSNNQKIVNL KEKVAQLEAQ CQEPCKDTVQ IHDITGKDCQ DIANKGAKQS GLYFIKPLKA NQQFLVYCEI DGSGNGWTVF QKRLDGSVDF KKNWIQYKEG FGHLSPTGTT EFWLGNEKIH LISTQSAIPY ALRVELEDWN GRTSTADYAM FKVGPEADKY RLTYAYFAGG DAGDAFDGFD FGDDPSDKFF TSHNGMQFST WDNDNDKFEG NCAEQDGSGW WMNKCHAGHL NGVYYQGGTY SKASTPNGYD NGIIWATWKT RWYSMKKTTM KIIPFNRLTI GEGQQHHLGG AKQVRPEHPA ETEYDSLYPE DDL
Explore Fibrinogen gamma chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets